- Home
- LU vs HCM Comparison
LU vs HCM Comparison
Compare LU & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LU | HCM |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | China | Hong Kong |
| Employees | N/A | 1811 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LU | HCM |
|---|---|---|
| Price | $2.29 | $14.38 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | ★ 1.4M | 19.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $28.37 |
| Revenue Next Year | $22.52 | $17.50 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.28 | $11.51 |
| 52 Week High | $4.57 | $19.50 |
Technical Indicators
Market Signals| Indicator | LU | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 31.64 | 54.64 |
| Support Level | N/A | $14.42 |
| Resistance Level | $2.77 | $15.49 |
| Average True Range (ATR) | 0.09 | 0.46 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 1.50 | 72.93 |
Price Performance
Historical ComparisonAbout LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.